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11 INTRODUCTION
Reporting of unmodified study results is one of the main standards in research
ethics. It is, however, common in clinical trials not to publish undesired study
results (1-3) as well as leave certain outcomes out of the publication or report
them inadequately while unspecified outcomes can be reported as primary (4-5).
This phenomenon is called reporting bias and it can occur in study level or in
outcome level. The latter is called outcome reporting bias (ORB), which is defined
as the selection for publication of a subset of the original recorded outcome
variables on the basis of the result. It means that the study endpoints, which
investigators choose prior to initiating the trial and pre-specify in the trial protocol,
are changed or incompletely reported in the final publication, causing biased
study results.
The latest revision of World Medical Association’s (WMA) Declaration of Helsinki
(6), a consensus document in research ethics originally adopted in 1964, says
the following about research publication and dissemination of results:
“Researchers, authors, sponsors, editors and publishers all have ethical
obligations with regard to the publication and dissemination of the results of
research. Researchers have a duty to make publicly available the results of their
research on human subjects and are accountable for the completeness and
accuracy of their reports. All parties should adhere to accepted guidelines for
ethical reporting. Negative and inconclusive as well as positive results must be
published or otherwise made publicly available. Sources of funding, institutional
affiliations and conflicts of interest must be declared in the publication. Reports
of research not in accordance with the principles of this Declaration should not
be accepted for publication.”
ORB includes both omitting and introducing outcomes as well as changing the
order of their importance (7). Accordingly, outcome reporting bias either limits the
efficacy or harm data of an intervention or emphasizes certain results over others,
which may lead to unsound conclusions about a treatment. In order to reliably
2assess ORB one needs to compare published articles to original trial protocols.
However, full trial protocols are not currently available for public, but they are
controlled by national research authorities, which creates a challenge in
interpretation of clinical trial results. (8) Hence, a serious problem in ORB resides
in applying research results in practice. Even though selective reporting of
outcomes, as such, is an ethical problem, the actual threat is that it can distort
the interpretation of efficacy or harm outcomes of an individual treatment and
consequently may risk the patient safety.
2 REVIEW OF THE LITERATURE
2.1 Publication bias
Publication bias has got a lot of attention during the last few years. It seems to be
more widely recognized and understood than its “little sister” outcome reporting
bias. Publication bias in clinical trials has been studied quite a lot in different areas
of medical research (1-5) and there is rather much recent evidence of the
frequency of publication bias (9-11). A systematic review by Dwan et al. (9) shows
that publication bias is prevalent. In the review the publication rate of randomized
controlled trials (RCTs) had, however, a great variation from 21% to 93%. But
when this range was divided into positive and negative results it was seen that
trials with positive results had less variation (60% - 98%) than those with negative
results (19% - 85%). The review suggests that trials with positive and statistically
significant results are more likely to be published.
Efforts have been made to reduce publication bias. These include, for instance,
prospective trial registration, peer review process and open-access publishing.
However, none of these have been shown to be very effective (12). Publication
rate in clinical trials still remains low (10, 11).
32.2 Outcome reporting bias
Selective reporting of outcomes has not been as much discussed as publication
bias, but it is only quite recently more widely recognized. It is important to
understand these biases as they both create a potential threat to reliability of
medical research. Even though it is not very meaningful to separate publication
bias and ORB too much from each other, I will now concentrate more on the
latter.
It has been shown in many studies that outcome reporting bias in clinical trials is
common (1-5, 13-22). ORB includes omitting outcomes from publication that were
mentioned in the protocol, introducing new outcomes in published article that
were not listed in the protocol and changing primary outcomes to non-primary or
vice versa. Studies have been shown that all of these forms of ORB are prevalent
(4, 14). In one of the first large studies on ORB Chan et al. (4) found that of the
inconsistently reported outcomes 46% were changed (primary to non-primary or
vice versa), 26% omitted and 17% introduced. In a quite recent study by Fleming
et al. (16) 39% of non-primary outcomes were omitted and 44% introduced.
There is still rather few studies that have actually determined reporting of the
outcomes by comparing publications to full original protocols. Chan et al. had the
access of full trial protocols in two separate studies (4, 5) and found that a third
or more of trial outcomes were incompletely reported. Al-Marzouki et al. (13) also
compared protocols to published reports and found that 29% of trials had major
differences in primary outcome. Other studies show similar findings. Hahn et al.
(17) found that only 40% of trials had pre-specified primary outcomes and 33%
of these reported the outcomes inconsistently in the final publication. In another
study, two thirds of the included trials had discrepancies between the protocol
and the published article in primary outcome and up to 92% of trials in secondary
outcomes (21).
Yet, there are ways to assess the existence of ORB in clinical trials without having
access to the original trial protocols. These include comparing trial registry entries
to final publications. This has been more extensively possible after 2005 when
4the International Committee of Medical Journal Editors (ICMJE) stated that all its
member journals start to require registration of all clinical trials prior to recruiting
first subject as a precondition for publication (23), which, as expected, led to a
remarkable increase in trial registration rates (24). In studies comparing trial
registry entries to published articles consistent numbers with those discussed
above are shown. A study that looked clinical trials of surgical interventions found
that 49% of included trials had some inconsistency between registered and
published outcomes (18). In two other studies, including RCTs from a broader
area of medicine, discrepancies between registered and published outcomes
were found in 31% of all outcomes (19), in 31% of primary outcomes and 70% of
secondary outcomes (15). Nevertheless, a quite recently published study found
discrepancies in only 18% of primary outcomes but 64% of non-primary outcomes
(16) suggesting that reporting of primary outcomes in trial registries and
publications might be improving, yet the rate of overall discrepancies remains
high.
Apart from the two already presented ways of studying ORB, there is a number
of studies where a multiple point classification system has been introduced in
order to detect missing or incompletely reported outcome data (25, 26). Even
though only presenting an estimate of the frequency of ORB, the results of these
works are also consistent with the ones comparing publications with original
protocols. To my knowledge, a study that compares publications to both trial
protocols and registry entries has not been conducted before, making our
ongoing study (27) to be presented in chapter 3 the first one of that kind.
There is clear evidence that statistically significant outcomes have higher odds
for being completely reported than statistically insignificant ones (4, 5, 14, 18, 19).
According to Chan et al. (5) the difference is remarkable, statistically significant
outcomes having more than two times higher probability for being fully reported.
Studies in which the reasons for omitting outcomes have been asked by
contacting the authors of the publication, the most common answers included
need for brevity or space constraints imposed by journals, lack of statistical
significance, lack of clinical importance, lack of understanding about the
5importance of reporting “negative” results and there being too few events worth
reporting (14, 20). In one study 86% of contacted trialists denied the existence of
unreported outcomes (4). These findings suggest that researchers do not
recognize the problem lying in ORB and that it should be openly discussed more.
The influence of source of funding in ORB in clinical trials have also been
discussed, however, there is conflicting results concerning the question.
Bourgeois et al. (28) found that industry funded trials more often report positive
findings compared to non-industry funded trials; the proportion of publications
reporting positive results were 85% for industry funded, 50% for government
funded and 72% for nonprofit or nonfederal organization funded trials. Yet, no
association between change of primary or non-primary outcome and source of
funding were found in the study by Fleming et al. (16).
An interesting question is, how ORB effects on treatment decisions. Clinical
decision-making is largely leaning on research evidence from RCTs (29-31).
Systematic reviews and meta-analyses represent the best available evidence as
they gather and analyse results of all relevant RCTs investigating a certain
healthcare intervention in order to provide a summary of the results and to reduce
possible biases in individual trials. Many national guidelines and
recommendations for treatment are made based on high-quality systematic
reviews, such as Cochrane reviews. (32) However, if the pool of analysed
outcomes in individual RCTs is distorted favouring positive and scientifically
significant results, the results of reviews and meta-analysis are likely to
overestimate the efficacy of health care interventions (9).
Moreover, the selective reporting of negative study results creates a possibility to
perhaps an even more serious threat: underestimation of treatment harm. It has
been shown that harm outcomes more often are inadequately reported than other
outcomes (5) and that non-published trials include more information about
adverse events than published reports (33). Recent research evidence suggests
that ORB for benefit outcomes is prevalent in over a third of reviews (25) and
ORB for harm in more than 80% of systematic reviews (26). According to Kicinski
et al. (10) outcomes favouring treatment are on average 27% more likely to be
6included in meta-analysis than those not favouring treatment and results with no
evidence of adverse effects are up to 78% more likely to be included than those
showing that adverse effects exist. Hence, study evidence shows that ORB is
also prevalent in systematic reviews and meta-analyses, which is a serious threat
to the whole evidence based medicine, and, moreover, ORB seems to involve
harm outcomes even more than other outcomes.
2.3 Clinical trial protocols
Trial protocol is a study plan where investigators describe how the trial will be
conducted and report essential information about the trial (rationale, design,
objective, study population, outcomes, statistical methods, time frame, sponsor
etc.). Clinical trial protocol should be done prior to initiation of the trial and
submitted to national ethics committee for approval. (6) Clinical trial protocols
have been found to have a large amount of variation in completeness of reporting.
Therefore, international guidelines for reporting in protocols have been made to
improve the quality of trial protocols. (36) While The CONSORT (CONsolidated
Standards of Reporting Trials) (34) and The PRISMA (Transparent Reporting of
Systematic Reviews and Meta-analyses) (35) Statements guide with reporting
RCTs and systematic reviews, The SPIRIT (Standard Protocol Items:
Recommendations for Interventional Trials) Statement 2013 (36) provides a 30
point checklist of minimum information that should be described in clinical trial
protocols, including administrative information, introduction, participants,
interventions, outcomes, assignment of interventions (for controlled trials), data
collection, management, analysis, monitoring, ethics and dissemination and
appendixes.
Full trial protocols that are submitted to the research authorities are confidential
and not currently available for public. Work has been done to make protocols
publicly available and thus increase transparency of medical research: medical
journals have started to require study protocol when submitting a trial for
7publication (37-39) and trial registries provide public with the basic information
from protocols (23, 40) but none of these gives access to full original trial
protocols leaving a lot information still unavailable. This makes the complete
assessing of ORB challenging.
2.4 Trial registration
The Declaration of Helsinki 2013 (6) gives a clear statement for trial registration:
“Every research study involving human subjects must be registered in a publicly
accessible database before recruitment of the first subject.” Moreover, WHOs
Statement on Public Disclosure of Clinical Trial Results (41) says: “Before any
clinical trial is initiated (at any Phase) its details are to be registered in a publicly
available, free to access, searchable clinical trial registry complying with WHOs
international agreed standards. The clinical trial registry entry should be made
before the first subject receives the first medical intervention in the trial.” However
39% of all RCTs published in 2010 had not been registered, yet the range is wide
between different research areas and journals, registration rate of published
articles varying from 21% to 87% (42). Furthermore, there is quite a remarkable
discrepancy between the outcome information in trial registries and publications.
Norris et al. (43) found that only 50% of index outcomes were mentioned in
registries and for 90% of included RCTs there were some evidence of selective
outcome reporting or selective analysis reporting. Regardless of the wide range
in registration rates, these numbers question the benefit of trial registration in
reducing reporting biases.
In addition to trial registration, other efforts have been made to reduce ORB in
clinical trials. In October 2015 Compare Project (The Center of Evidence Based
Medicine Outcome Monitoring Project) was initiated in order to detect switching
of outcomes and to provide a full open access to the outcome discrepancy data.
The Compare Project Team compares every trial report published in top five
medical journals (NEJM, JAMA, The Lancet, Annals of Internal Medicine, BMJ)
8to its most original protocol found in trial registry and records the changes in
outcome data. In the Compare website all this up-to-date data is collected and
visible to anybody. (44)
2.5 Research ethics committees
All medical research is regulated and supervised by national research ethics
committees (RECs), but the REC system varies a lot from country to country. In
Finland there are five regionally operating RECs handling clinical research, one
in each university clinic. HUS (The Hospital District of Helsinki and Uusimaa)
research ethics committee is the biggest committee in Finland and works in
cooperation with the University of Helsinki. HUS REC is divided into 4
subcommittees that together are in charge of all clinical trials in HUS area and in
the university hospital district of Helsinki. In addition to the regional committees
there is a central REC called TUKIJA (the National Committee on Medical
Research Ethics) that operates nationally and is mostly concentrated on
multicenter drug trials. (45, 46)
Compared to other countries there is a very small number of RECs operating in
Finland and unlike in many other countries, there are no private RECs. The
number of RECs in Finland has been reduced from 22 to 6 in 2010, presumably
in order to rationalize their work. What is surprising, though, even alarming, is
that although existence of these six RECs in Finland is defined by the law, their
function is not supervised by anyone but the committees themselves. (45, 46).
According to the Finnish medical research law, all trials involving human subjects
have to apply a research permit from one of the six operating RECs in Finland.
The correct REC is determined by the working place of the principal investigator.
Applications with their many appendixes are submitted to the given REC by the
principal investigator of the trial.
9During the data collection, which will be described in detail in chapter 5, I had the
opportunity to follow the work of the HUS research ethics committees from a
distance as the data collection was conducted in their facilities. From my
perspective, the work in the HUS committees seemed to be well organized and
people I encountered (mainly assistants) seemed to be dedicated to their jobs.
The work in HUS REC seemed to be quite regulated and to include a lot of
bureaucracy, but the main idea still seemed to be to help researchers instead of
hindering their work. However, I did not have a chance to follow an official
meeting of the HUS REC, so my observations of the operation of the committee
is quite superficial.
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3 BACKGROUND OF THE REPORT
My data collection was a part of a Canadian-Finnish study (27), where we
compared original trial protocols approved in Helsinki in 2002 and 2007 to trial
registries and final publications. The paper by Chan et al. (27) is soon to be
submitted for publication. The objectives of this inception cohort study were to
determine 1) completeness of protocols and registry records, 2) registration and
publication rates, 3) consistency in primary outcomes and 4) impact of registration
on publication and outcome reporting. The study cohort included A) all clinical
trial protocols and amendments approved by HUS REC in 2002 and 2007 and
TUKIJA National Committee on Medical Research Ethics in 2007 as well as B)
corresponding registry records from trial registers and C) corresponding
publications searched from various publication files, such as Medline. To my
knowledge this study is the first comparing all these three sources for researching
reporting bias.
4 AIM OF THE REPORT
Purpose of this report is to 1) present the basic data collection, 2) illustrate the
usefulness and difficulties in using REC submissions to study publication and
outcome reporting bias, and 3) review the preliminary results of the above
mentioned study (27) as reported by An-Wen Chan in REWARD EQUATOR
Conference on September 29th 2015.
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5 MY DATA COLLECTION AND OBSERVATIONS
As a part of the above mentioned study I collected a large data from trial protocols
in Helsinki. The purpose of the data collection was to record the original protocol
data for the inception cohort study (27), in which completeness and consistency
of reporting in protocols vs. trial registries and published reports were determined.
I reviewed under seven months in 2011 all clinical trial protocols submitted to the
HUS research ethics committees in 2002 and 2007 and all HUS area trials
submitted to TUKIJA National Committee on Medical Research Ethics in 2007.
TUKIJAs 2002 submissions were not included for logistic reasons. These
research ethics committees were chosen for collecting the inception cohort
because together they (HUS and TUKIJA) compose the biggest RECs in Finland
handling a lot of multicenter RCTs. Also, HUS and TUKIJA RECs are located in
Helsinki, which was convenient for us.
Our definition of a trial was: a prospective study, where healthcare interventions
are actively assigned to participants to test their effects and outcomes are
measured to evaluate the effects of the interventions. We excluded all extensions
to earlier than 2002 or 2007 initiated studies (secondary reports),
pharmacokinetics and diagnostic test properties.
Clinical trial submissions to RECs were rather extensive. In addition to the
application page the submission included the protocol, investigators’ guide,
multiple ethical and other reports by the principal investigator and documents to
be given to the subjects. I collected data only from the trial protocols. However,
contact information of the investigators could be taken from other parts of the
submission, since contact information was collected only for locating
corresponding trial publications in the later phase.
In HUS REC all the submission material was located in paper files in HUS ethics
boards archive. There were some challenges in finding and collecting all the files.
Firstly, the archive was located quite far from my desk and all the files from 2002
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and 2007 had to be moved from the archive to the office. Secondly, some of the
files were not in the correct place in the archive and had to be searched for. Two
of the files were never found and obviously these trials had to be excluded from
the study. In TUKIJA the submission material was also located in an archive, but
the files were moved from the archive and back by TUKIJAs own employees. It
seemed that there were no difficulties in locating the correct files and all of the
included submissions were found. Yet, in TUKIJA there were much less
submissions than in HUS REC.
The submission material was well organized in the files in both HUS and TUKIJA,
and thus the protocols were easily found with one exception in HUS REC, when
the file did not include any protocol. However, information from the protocols was
sometimes hard to find. In some cases the information we were looking for was
not mentioned in the protocol, but was found or could be concluded from other
parts of the submission.
5.1 Permissions for data extraction
Submissions for RECs, including protocols, are confidential documents. In order
to be able to extract the data from trial protocols we had to apply research
permission from the Ministry of social affairs and health for the whole study and
moreover from HUS REC and TUKIJA separately for extracting their
submissions. Getting the permission for reviewing trial protocols was not a simple
process. There was a lot of bureaucracy in the process, especially with TUKIJA.
It had strict regulation and very precise procedures for sharing their submission
data. In order to ensure the protection of the confidential trial data, both HUS and
TUKIJA demanded that the data collection had to be conducted in their own
facilities under supervision. Collected data files had to be well protected and
paper copies of the protocol sections (HUS) had to be preserved carefully to
make sure that any third party could not get access to the documents.
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In HUS REC we were granted permission for extracting information from trial
protocols and applications and also for copying the sections ‘outcomes’,
‘statistical analyses’ and ‘sample size calculation’ for later reviewing. Information
from the photocopied sections was later extracted and analyzed by An-Wen Chan
with his study group in Canada.
TUKIJA did not grant us a permission to take any photocopies. Accordingly, I had
to type all the information needed for the study, also the outcome, statistical
analyses and sample size calculation data, which meant a lot of writing. It was
quite hard for me to decide which information inside these sections would be
relevant for the study, since I was not the one to review and analyze these
sections. Thus, I transliterated almost all text from the sections 'outcomes',
'statistical analyses' and 'sample size' to ensure that any relevant data would not
be left out. This made the data collection in TUKIJA slow, even though there were
much less trial submissions compered to HUS REC.
Furthermore, we translated all the Finnish data (trial titles and photocopies from
Finnish protocols) to English in order to enable the study group in Canada to
review and analyze the data. Translation work was conducted during the year
2012. There were in total 100 trial protocols in Finnish. Trial titles were translated
by me with the help of NETMOT dictionary by Kielikone Ltd on the intranet of
Helsinki University, whereas the material from the photocopies (outcomes,
statistical analysis and sample size calculation) was translated by the principal
investigator of the study Elina Hemminki. The latter was quite substantial work
and much more time-consuming than translation of the trial titles.
5.2 Collecting the data from the protocols
There were 265 protocols in total, out of which 139 was from 2002 (83 in English,
56 in Finnish) and 126 was from 2007 (82 in English, 44 in Finnish). 9 of the 2007
protocols were submitted to TUKIJA and the rest were submitted to HUS REC.
Table 1 illustrates the data characteristics listing the number of protocols
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submitted to HUS and TUKIJA and the number of single-center/ multicenter trials
as well as academic/ industry funded trials. From the total number of the protocols
38% was in Finnish. Trials that had protocols written in Finnish were usually
single-center studies and they were more often academically funded than trials
with English protocols. Table 2 shows the percentage of industry vs. academically
funded and single-center vs. multicenter trials in Finnish and English protocols in
2002 and 2007.
Table 1. Data characteristics. Protocols submitted to HUS and TUKIJA, numbers.
HUS 2002 HUS 2007 TUKIJA 2007
single-center 51 27 1
multicenter 86 90 8
industry funded 70 57 9
academic 20 19 0
protocols in Finnish 56 44 0
protocols in English 83 73 9
total 139 117 9
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Table 2. Proportions (numbers) by language of the application and trial
characteristics.
Finnish
protocols
2002
English
protocols
2002
Finnish
protocols
2007
English
protocols
2007
single-center 73% (n=41) 12% (n=10) 55% (n=24) 5% (n=4)
multicenter 25% (n=14) 87% (n=72) 45% (n=20) 95% (n=78)
industry funded 8% (n=5) 78% (n=65) 2% (n=1) 79% (n=65)
academic 30% (n=17) 4% (n=3) 36% (n=16) 4% (n=3)
Variables to be collected were agreed with the principal author of the forthcoming
publication (An-Wen Chan). These variables are listed in Appendix. Some of the
information (contact information) was collected for finding the final reports, but
most of the data was collected to determine the completeness of reporting in
protocols and for later comparison to publications and registry entries in order to
study discrepancies between protocols, trial registries and final reports.
In addition to the variables listed in the Appendix, in HUS REC we took
photocopies of the ‘outcomes’, ‘statistical analyses’ and ‘sample size calculation’
sections of the protocols for later reviewing. We decided to copy these sections
rather than extract the relevant data, because the amount of information under
these titles was very large and the nature of this information was very specific.
Also, we considered it to be a difficult and time-consuming task for a person who
do not have a lot of experience in this area to summarize the relevant information
from all of these three sections (outcomes, statistical analyses and sample size
calculation). However, from TUKIJA submissions we were not allowed to take
any photocopies, hence, in TUKIJA I had to transliterate the information under
these subheadings.
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Office Exel was used for data collection. The Exel sheet was created according
to the variables that we planned to collect. For protocol sections ‘outcomes’,
‘statistical analyses’ and ‘sample size calculation’ in TUKIJA’s submissions we
used Office Word for transliterating. The photocopies from HUS protocols were
collected and organized in folders according to the year (2002 or 2007) and
protocol number. The folders (one for each year) were kept in the HUS REC’s
office during the data collection. During the later study period they were kept
locked in Elina Hemminki’s office at THL.
Data collection was time-consuming. Finding information from the protocols
sometimes required reading the whole protocol or large parts of it. Some of the
study protocols, especially protocols of international drug trials, were very
extensive and long making the data extracting laborious. Almost all the English
protocols were multicenter trials with industry sponsor and these protocols
usually followed a certain pattern in reporting. These protocols were often well
structured and usually contained most of the information we were collecting, but
on the other hand they were usually very long, sometimes containing more than
100 pages, and exhausting to read. Furthermore, they contained a lot of difficult
terminology, which made it sometimes hard to extract the data. Smaller,
academic trials, often having the protocols written in Finnish, sometimes had
protocols with only a single page, being very easy to read and to find information
from, but on the other hand, often lacked relevant data. In some cases, however,
they succeeded to have a lot of relevant information summarized in one page
whereas many industry funded trials still had deficiencies in reporting, even
though the protocols seemed extensive. Nevertheless, it is noteworthy that for
me Finnish protocols were easier to read and understand as Finnish is my mother
tongue.
When generalizing, it could be said that Finnish protocols of national,
academically funded trials were compact and reader-friendly, but had quite many
deficiencies in reporting. On the contrary, English protocols of international,
multicenter, industry funded trials were long, structured and complete, yet quite
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opaque. Nevertheless, the obvious conclusion of the quality of the trial protocols
was that they had a lot of variation.
The best way of reporting in protocols probably lies somewhere in the middle. In
my opinion short and compact protocols would be more convenient, but the
importance of complete reporting cannot be overlooked. However, from my
perspective, it is equally important that the protocols are understandably written.
The SPIRIT Checklist (36) provides a practical tool for improving the
completeness of reporting in protocols, whereas protocol authors should pay
attention to clearness and compactness of the protocols, so that anyone could
understand them.
5.2.1 Limitations of the data collection
Using this kind of multiphase method for researching selective reporting involves
a risk for reporting errors itself. The fact that protocols we were reviewing were
on paper and every single protocol had to be picked up from the archive, makes
mixing up the trial protocols unlikely. However, data collection and filling up
information in Exel sheet required meticulousness and there were no systematic
double checking of the collected information, hence the possibility for human
errors exists.
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5.3 Processing of the data
As a result of my data collection two 46-variable Exel sheets were formed, one
for 2002 and one for 2007 trials. This data included in total 265 trials. Some of
the unambiguous information (i.e. reported/ not reported) was coded for
analyzing. The finalized data included also photocopies/ transcribed documents
of ‘outcomes’, ‘statistical analyses’ and ‘sample size calculation’ sections of the
trial protocols. The photocopies were scanned to computer and all the data was
sent as protected files to An-Wen Chan. The photocopies and the Word files from
TUKIJA protocols were reviewed by him and his study group in Canada.
Our study group in Finland helped to search the Finnish publications form Finnish
national research databases, but otherwise all the later phases of the study were
conducted in Canada. Processing of the data had many phases and, unlike the
data collection, multiple people executing it. People working both in Finland and
in Canada and cooperating in data processing added its own challenges, but did
not cause any bigger problems.
The whole process of data collection was time-consuming and somewhat
cumbersome, but in my opinion, it was worth the hard work for many reasons.
First of all, there are not many studies like this one, where final reports of clinical
trials have been compared to original protocols, which is the most reliable method
for determining ORB. Secondly, the data collected from the protocols was
extensive and thus has given a unique possibility to research the completeness
of reporting in wide spectre. Finally, this study is, to my knowledge, the first to
compare all three sources: protocols, trial registries and final publications.
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6 PRELIMINARY RESULTS ON REPORTING BIAS
Below I will summarize the preliminary results of the study as presented by An-
Wen Chan in REWARD EQUATOR Conference on September 29th 2015 (27).
This cohort differs slightly from my data presented earlier in this dissertation,
because six of the trials (three from 2002 and three from 2007) were excluded
from the study after the data collection was finalized.
6.1 Cohort characteristics and completeness of reporting in protocols
The inception cohort consisted of 259 trial protocols out of which 123 were
submitted in 2007 and 136 in 2002. The cohorts in 2002 and 2007 were quite
similar to each other both in characteristic and in completeness of reporting. The
only clear differences between the years were that there were less multicenter
trials in 2002 (2002: 63%, 2007: 78%) and the median sample size was bigger in
2007. In 2002 the median sample size was 140 (range 40-420) and in 2007 200
(72-732). Most of the trials were randomized (2002: 86%, 2007: 88%) and parallel
group (2002: 77%, 2007: 81%), more than two-thirds were drug trials (2002: 69%,
2007: 67%) and a half of the trials were industry funded (2002: 51%, 2007: 53%).
Most of the trial protocols reported protocol date and eligibility criteria completely,
Table 3. Also primary outcome and blinding were reported well (only RCTs
included), Table 4. However, role of sponsor and interim analysis as well as
sequence generation and allocation concealment (only RCTs taken) were
completely reported in only half of the trial protocols (Tables 3 and 4).
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Table 3. Completeness of reporting in protocols.
2002 (n=136) 2007 (n=123)
Protocol date 116 (85%) 108 (88%)
Protocol version 79 (58%) 85 (69%)
Eligibility criteria 133 (98%) 116 (94%)
Interim analysis 51 (37%) 58 (47%)
Role of sponsor 68 (50%) 56 (55%)
Table 4. Completeness of reporting in protocols, only RCTs included.
2002 (n=117) 2007 (n=108)
Primary outcome 95 (81%) 89 (82%)
Blinding 91 (78%) 90 (83%)
Sequence generation 49 (42%) 61 (56%)
Allocation concealment 66 (56%) 61 (56%)
6.2 Completeness of registration
Since clinical trial registries were not in a wide use in 2002, completeness of
registration was only determined for the 2007 cohort. 63% of all 2007 trials and
64% of all 2007 randomized trials were registered. From WHO Trial Registration
Data Set criteria, countries (100%), health condition (100%) and sample size
(100%) were completely documented in the registries. Also outcomes (95%),
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eligibility criteria (94%) and funder (84%) were documented in most cases. On
the contrary only 51% of registered trials documented information about the
intervention and only 6% documented a scientific contact.
6.3 Completeness of publishing and reporting of outcomes
During the time of 2002-2015, 49% of both cohort trials were published (in 2002
the number was 66 and in 2007 60). The publication rate was about the same for
randomized trials (2002: 49%, 2007: 51%) as for all trials. The median publication
year was 2007 (range: 2003-2014) for the 2002 initiated trials and 2011 (range:
2008-2015) for the 2007 initiated trials. Results on ORB, as well as all the final
results from the study (27) will be presented in final report soon to be published.
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7 DISCUSSION
Publication bias and selective reporting of outcomes are prevalent problems,
which distort the results of healthcare interventions, mainly by overestimating
their efficacy or underestimating their harm. This may lead to using ineffective
treatments and, at its worse, may jeopardize patient safety. Furthermore, not
publishing trial results or omitting outcomes from the published article can be
considered as limiting availability of scientific knowledge and wasting the overall
resources for medical research.
It is quite difficult and time-consuming to research publication bias and ORB.
There are multiple ways of assessing the existing of selective reporting but our
method (comparing original protocols to publications) is so far the only accurate
one. This method is, however, quite cumbersome, multiphase and requires a lot
of permissions and other bureaucracy. These studies are, however, important in
order to illustrate the frequency and extent of the problem.
Work has been done to improve the situation. Trial registries, The SPIRIT (36),
The CONSORT (34) and The PRISMA (35) Statements, ethical statements by
WHO and WMA, requirements of medical journals, COMPARE project (44) and
several other efforts have given the problem of selective publishing and reporting
more publicity and are guiding research community to the right path. Still, no
sufficient improvement or adequate solution for the problem have been found.
Next step in this path might be releasing full trial protocols and increasing
transparency in the work of RECs. Making trial protocols available for public
would help detecting selective reporting and reduce its existence, resulting in
enhancing reliability of clinical trial results. Open access to full trial protocols
would also simplify researching of ORB. However, it is also necessary that
reporting in protocols is complete as well as compact and clear to make sure
everyone can read them.
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Furthermore, independent researchers have a great responsibility in reporting
trial outcomes completely and publishing all trial results, even non-significant and
negative ones. In Finland, the medical research law doesn’t say anything about
publishing the trial results, so for now, the onus is on the trialists. Also, peer
reviewers and medical journals has an opportunity and thus responsibility to
intervene when noticing selective reporting in clinical trial reports. Better
knowledge and more extensive discussion among researchers about the matter,
especially about less widely recognized ORB, would presumably help reducing
selective reporting. Much has been done, but there is still need to actively search
for solutions for reducing publication bias and ORB. This is crucial for remaining
the good level of evidence based medicine, on which all clinical decision-making
is leaning.
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IAPPENDIX
List of variables for data collection.
Variable Alternatives/ Explanation Source
1. Protocol number number REC’s arciving system
2. Study number number application
3. Trial yes/ no/ unclear own judgement
4. Study title protocol
5. Speciality protocol
anesthesiology
cardiology
dermatology
endocrinology
general practise
gynegology
hemathology
infectious diseases
internal medicine
neurology
oncology
ophtalmology
orthopedics
otorhinolaryngology
pediatrics
pharmacology
physiology
psychiatry
radiology
rheumatology
surgery
urology
other
II
Variable Alternatives/ Explanation Source
6. Funding protocol
industry
partial industry
academic
government
private
health services
other
none
not reported
7. Investigators names application or protocol
-principal inverstigator
-other investigators in Finland
-other international investigators
8. Contact information (PI) application
-phone number
-e-mail address
9. Protocol information reported/ not reported/ unclear protocol
-protocol version
-protocol date
-protocol authors
10. Sites protocol
single-center
multicenter
11. Phase protocol
pilot
1
2
3
4
III
Variable Alternatives/ Explanation Source
12. Design protocol
parallel
cross-over
split
cluster
non-controlled
13. Framework protocol
superiority
non-inferiority
equvivalence
non-controlled
14. Intervention protocol
drug
surgery
procedure
other substance
other therapy
device
lifestyle
counselling
education
managemet strategy
diagnose test
15. Name of the intervention name of the drug/surgical
technique etc.
protocol
16. Intervention group intervention more detailed: dose,
administation etc.
protocol
17. Control groups: name of the control
intervention(s)
protocol
-control group 1
-control group 2 etc.
18. Overall sample size number protocol
19. Number of groups number protocol
IV
Variable Alternatives/ Explanation Source
20. Allocation ratio ratio (eg. 1:1) protocol
21. Randomization: protocol
-allocation
full individual randomization
cluster randomization
split-body
other
-sequence generation
computer generated
random tables
lottery
other
-allocation concealment
mechanism
sealed envelopes
calling to a person
calling to a computer
other
22. Blinding label protocol
single
double
triple
open-label
blinded
no blinding
not reported
23. Blinding: protocol
-patient yes/ no/ not reported/ unclear
-caregiver yes/ no/ not reported/ unclear
-investigator yes/ no/ not reported/ unclear
-outcome assessor yes/ no/ not reported/ unclear
-data analyst yes/ no/ not reported/ unclear
VVariable Alternatives/ Explanation Source
24. Eligibility criteria reported/ not reported/ unclear protocol
25. Duration of the trial time protocol
-duration of the intervetion
-duration of the follow-up
26. Interim analysis: protocol
yes → how often
no
not reported
unclear
-statistical anlysis plan yes/ no
-data monitoring committee yes/ no/ not reported/ unclear
27. Role of sponsor in: protocol
-study design reported/ not reported/ unclear
-data collection reported/ not reported/ unclear
-management reported/ not reported/ unclear
-analysis reported/ not reported/ unclear
-interpretation reported/ not reported/ unclear
-writing manuscript reported/ not reported/ unclear
28. Amendments yes/no
if yes: how many, relevant
changes, date of the
amendements
protocol amendments
